Cytoreductive surgery and hyperthermic intrapleural chemotherapy for malignant pleural diseases: preliminary experience

Cytoreductive surgery and hyperthermic-intraoperative-intrapleural-chemotherapy (HITHOC) is a known approach for malignant pleural diseases (MPD). This study was started to clarify the role of cytoreductive surgery and HITHOC in MPD. Criteria of inclusion were early-stage disease in malignant pleura...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2015-01, Vol.11 (2s), p.47-52
Main Authors: Migliore, Marcello, Calvo, Damiano, Criscione, Alessandra, Viola, Cristina, Privitera, Giuseppe, Spatola, Corrado, Parra, Hector Soto, Palmucci, Stefano, Ciancio, Nicola, Caltabiano, Rosario, Maria, Giuseppe Di
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - secondary
Adenocarcinoma - surgery
Adenocarcinoma - therapy
advanced lung cancer
Aged
Antineoplastic Agents - therapeutic use
Care and treatment
Chemotherapy
Cisplatin - therapeutic use
Cytoreduction Surgical Procedures - methods
cytoreductive surgery
Diagnosis
Female
HITHOC
Humans
Hyperthermia, Induced - methods
hyperthermic perfusion
lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Lung Neoplasms - surgery
Lung Neoplasms - therapy
Male
mesothelioma
Mesothelioma - drug therapy
Mesothelioma - pathology
Mesothelioma - surgery
Mesothelioma - therapy
Mesothelioma, Malignant
Middle Aged
multimodality treatment
Pleural diseases
Pleural Neoplasms - drug therapy
Pleural Neoplasms - secondary
Pleural Neoplasms - surgery
Pleural Neoplasms - therapy
Prospective Studies
Thoracic surgery
Thoracic Surgical Procedures - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cytoreductive surgery and hyperthermic-intraoperative-intrapleural-chemotherapy (HITHOC) is a known approach for malignant pleural diseases (MPD). This study was started to clarify the role of cytoreductive surgery and HITHOC in MPD. Criteria of inclusion were early-stage disease in malignant pleural mesothelioma (MPM), young age, good condition and selected stage-M1a lung cancer. Six patients with MPM and two patients with lung cancer were enrolled. After surgical debulking, intrapleural cisplatin was administered for 60 min at 42.5°C. Wedge, rib resection and repaired diaphragm were added in three, one and one patient, respectively. Morbidity, toxicity and mortality was nil. Hospital stay was 8 days. Mean survival is 13.6 months. This experience confirms that cytoreductive surgery and HITHOC is a good option in the treatment of MPD. A randomized controlled trial is necessary.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon.14.256